These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37775345)

  • 41. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Grimfjärd P; Lagerqvist B; Erlinge D; Varenhorst C; James S
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):151-157. PubMed ID: 30698669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status of data on cangrelor.
    Qamar A; Bhatt DL
    Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention.
    Badreldin HA; Carter D; Cook BM; Qamar A; Vaduganathan M; Bhatt DL
    Am J Cardiol; 2017 Aug; 120(3):359-361. PubMed ID: 28576266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL;
    J Am Coll Cardiol; 2017 Jan; 69(2):176-185. PubMed ID: 28081827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide.
    Yun AN; Toyoda AY; Solomon EJ; Roberts RJ; Ji CS
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):383-389. PubMed ID: 35255052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
    Angiolillo DJ; Bhatt DL; Steg PG; Stone GW; White HD; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Mahaffey KW; Harrington RA
    J Thromb Thrombolysis; 2015 Oct; 40(3):317-22. PubMed ID: 26024789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.
    Sardar P; Nairooz R; Chatterjee S; Mushiyev S; Pekler G; Visco F
    J Thromb Thrombolysis; 2014 Jul; 38(1):1-10. PubMed ID: 24057605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cangrelor for treatment of arterial thrombosis.
    Walsh JA; Price MJ
    Expert Opin Pharmacother; 2014 Mar; 15(4):565-72. PubMed ID: 24479981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cangrelor for the management and prevention of arterial thrombosis.
    Storey RF; Sinha A
    Expert Rev Cardiovasc Ther; 2016 Sep; 14(9):991-9. PubMed ID: 27362653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
    Tamborini Permunian E; Riva N; Guasti L; Squizzato A
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures.
    Cagnazzo F; Radu RA; Derraz I; Lefevre PH; Dargazanli C; Machi P; Morganti R; Gascou G; Fendeleur J; Rapido F; Costalat V
    J Neurointerv Surg; 2023 Dec; 16(1):88-93. PubMed ID: 36922032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
    Stone GW; Généreux P; Harrington RA; White HD; Gibson CM; Steg PG; Hamm CW; Mahaffey KW; Price MJ; Prats J; Deliargyris EN; Bhatt DL
    Eur Heart J; 2018 Dec; 39(46):4112-4121. PubMed ID: 30203006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
    Vaduganathan M; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2016 Jun; 9(6):e003612. PubMed ID: 27313282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perioperative cangrelor in patients with recent percutaneous coronary intervention undergoing liver transplantation: A case series.
    Succar L; Lopez CN; Victor DW; Lindberg SA; Saharia A; Sheth S; Mobley CM
    Pharmacotherapy; 2022 Mar; 42(3):263-267. PubMed ID: 35075688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical use of cangrelor: a real-world multicenter experience from South Italy.
    Pepe M; Larosa C; Cirillo P; Carulli E; Forleo C; Nestola PL; Ercolano V; D'Alessandro P; Giordano A; Biondi-Zoccai G; Moscarelli M; Palmiotto AI; Esposito G; Favale S
    Panminerva Med; 2022 Mar; 64(1):9-16. PubMed ID: 34060281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing the Use of Cangrelor in the Real World.
    Qamar A; Bhatt DL
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):5-16. PubMed ID: 27677505
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study.
    Johnson BV; Horton ER; Domenico C; Nathan AS; Fanaroff AC; Acker MA; Kolansky DM
    J Invasive Cardiol; 2021 Dec; 33(12):E998-E1003. PubMed ID: 34817395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.